EyePoint cuts 53% staff after Phase 3 wet AMD trial miss, pivots to DME program
EyePoint said its Phase 3 LUCIA trial of DURAVYU in wet age‑related macular degeneration did not achieve the primary non‑inferiority endpoint. The company will end the wet AMD program early, cut roughly 53% of its workforce and expects $30 million of annual cost savings with $9 million of one‑time separation charges. It will redirect resources to its diabetic macular edema Phase 3 trials, with topline results expected in the fourth quarter of 2027, and reported about $118 million of cash on hand.
Why it matters
The restructuring is projected to save $30 million per year and preserve $118 million of cash, extending the runway to fund the DME trials through late 2027 (the company reports this cash balance). Analysts at Jefferies, JPMorgan, Mizuho and RBC Capital downgraded the stock and cut price targets, citing the trial failure and cash‑burn concerns.
Key facts
- 1The LUCIA Phase 3 trial of DURAVYU in wet AMD failed to meet its primary non‑inferiority endpoint. finance.yahoo.com
- 2EyePoint will reduce its workforce by approximately 53% of positions. stocktitan.net
- 3The restructuring is expected to generate estimated annualized savings of about $30 million. stocktitan.net
- 4One‑time employee separation charges are estimated at roughly $9 million. stocktitan.net
- 5EyePoint had approximately $118 million in cash, cash equivalents and short‑term investments as of September 30, 2026. quiverquant.com
- 6Topline results from the two Phase 3 DME trials (COMO and CAPRI) are expected in the fourth quarter of 2027. quiverquant.com
Summary written by AlphAI AI Desk from 18 of 18 sources. Not investment advice. Figures are as stated by the linked sources.